AstraZeneca pours cash into research and development as it hikes sales forecasts
Drugs giant AstraZeneca has hiked 2014 sales forecasts for the second consecutive quarter as the FTSE 100 company settles down to normality after rebuffing a £69billion takeover approach from US rival Pfizer.
Boss Pascal Soriot, who defended the company’s independence by arguing its pipeline of potential new drugs was worth much more than Pfizer was offering, is pouring cash into Astra’s research and development operations.
The group has been boosted by a delayed US launch of copycat versions of its Nexium heartburn and ulcer medicine.
Investments: Drugs giant AstraZeneca has hiked 2014 sales forecasts for the second consecutive quarter
Soriot also said that recent changes to the US tax regime had removed the rationale for firms such as Pfizer to buy overseas companies in so-called inversion deals to shift their tax bases abroad. Pfizer could, however, still come back with a revised bid after November 26.
Astra said sales in the third quarter rose 5 per cent to £4.1billion. It is now expecting sales to grow in low single digit figures at constant exchange rates this year, having previously predicted annual sales would be flat.
Analyst Ketan Patel at Ecclesiastical Investment Management said the shift in Astra’s R&D strategy ‘looks set to deliver growth in 2017 and beyond for the company’ but added the speculation on Pfizer returning to make another bid would continue up to and beyond the lock-out period.
Like all big drug companies, patent expiries continue to worry investors, with top-selling cholesterol treatment Crestor due to lose protection in 2016. Astra has also been building up its cancer business.
Shares slipped 28.5p to 4591.5p.
Most watched Money videos
- BMW's Vision Neue Klasse X unveils its sports activity vehicle future
- Mini Cooper SE: The British icon gets an all-electric makeover
- How to invest for income and growth: SAINTS' James Dow
- MailOnline asks Lexie Limitless 5 quick fire EV road trip questions
- 'Now even better': Nissan Qashqai gets a facelift for 2024 version
- Tesla unveils new Model 3 Performance - it's the fastest ever!
- Skoda reveals Skoda Epiq as part of an all-electric car portfolio
- Mini celebrates the release of brand new all-electric car Mini Aceman
- 2025 Aston Martin DBX707: More luxury but comes with a higher price
- Land Rover unveil newest all-electric Range Rover SUV
- Blue Whale fund manager on the best of the Magnificent 7
- Mercedes has finally unveiled its new electric G-Class
- 86-year-old Peter's woes with a faulty smart meter that...
- Ikea pushes back opening of its Oxford Street store to...
- MARKET REPORT: S4 Capital shares soar as Sir Martin...
- ALEX BRUMMER: UK second to United States among G7 richest...
- BHP boss to meet his counterpart at takeover target Anglo...
- Jaguar Land Rover posts its biggest profit since 2015...
- How these four private equity trusts could help you cash...
- Footsie hits new high as economy roars back
- British Airways owner IAG set for bumper summer
- Should the Bank of England have cut interest rates...
- Households with emergency savings pots rises...
- My favourite 20 new cars for under £20,000 - by the...
- SMALL CAP MOVERS: Light Science Technologies sales flourish
- The government is asking motoring enthusiasts for help...
- Rightmove expects weaker ad revenue growth as more...
- BUSINESS LIVE: UK GDP grows 0.6%; IAG profits take off;...
- How criminals could use AI to scam Britons - and what can...
- BA owner IAG profits climb more than sevenfold